Search Press releases

26 Apr 2024

Acquisition of own shares

Read More
25 Apr 2024

UCB’s General Meeting of Shareholders 2024

Read More
25 Apr 2024

UCB off to a Good Start into 2024 – Progressing on its Growth Path for a Decade Plus

Read More
23 Apr 2024

Transparency notification FMR LLC

Read More
22 Apr 2024

UCB receives European Commission approval for BIMZELX[®]▼(bimekizumab) as the first IL-17A and IL-17F biologic for moderate to severe hidradenitis suppurativa

Read More
19 Apr 2024

Acquisition of own shares

Read More

Stay up-to-date on the latest news and information from UCB